# A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

> **NCT05374525** · PHASE4 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 287 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** APRETUDE
- **DRUG:** Cabotegravir OLI

## Key facts

- **NCT ID:** NCT05374525
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-18
- **Primary completion:** 2024-08-08
- **Final completion:** 2024-08-08
- **Target enrollment:** 287 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05374525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05374525, "A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05374525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*